Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 14 unusual trades.
Delving into the details, we found 14% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $721,270, and 10 were calls, valued at $1,045,138.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $960.0 to $1280.0 for Regeneron Pharmaceuticals over the last 3 months.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's significant trades, within a strike price range of $960.0 to $1280.0, over the past month.
Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | CALL | TRADE | NEUTRAL | 01/17/25 | $160.3 | $152.0 | $156.6 | $980.00 | $454.1K | 200 | 0 |
| REGN | PUT | TRADE | BEARISH | 06/20/25 | $99.0 | $91.5 | $96.0 | $1100.00 | $384.0K | 3 | 0 |
| REGN | PUT | TRADE | NEUTRAL | 12/18/26 | $112.0 | $102.0 | $107.0 | $1040.00 | $214.0K | 0 | 0 |
| REGN | CALL | TRADE | BEARISH | 06/20/25 | $58.0 | $55.0 | $55.0 | $1280.00 | $165.0K | 19 | 0 |
| REGN | PUT | TRADE | BEARISH | 01/17/25 | $33.5 | $27.3 | $31.3 | $980.00 | $90.7K | 117 | 0 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Following our analysis of the options activities associated with Regeneron Pharmaceuticals, we pivot to a closer look at the company's own performance.
Where Is Regeneron Pharmaceuticals Standing Right Now?
- With a trading volume of 322,187, the price of REGN is down by 0.0%, reaching $1063.89.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 37 days from now.
What The Experts Say On Regeneron Pharmaceuticals
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1195.6.
- An analyst from JP Morgan has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1150.
- Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $1200.
- An analyst from RBC Capital downgraded its action to Outperform with a price target of $1229.
- An analyst from Argus Research persists with their Buy rating on Regeneron Pharmaceuticals, maintaining a target price of $1170.
- Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1229.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
